The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis.

BACKGROUND Lower urinary tract symptoms (LUTS) are common and have been associated with the subsequent diagnosis of prostate cancer (PCa) in population cohorts. OBJECTIVE To determine whether the association between LUTS and PCa is due to the intensity of PCa testing after LUTS diagnosis. DESIGN, SETTING, AND PARTICIPANTS We prospectively followed a representative, population-based cohort of 1922 men, aged 40-79 yr, from 1990 until 2010 with interviews, questionnaires, and abstracting of medical records for prostate outcomes. Men were excluded if they had a previous prostate biopsy or PCa diagnosis. Self-reported LUTS was defined as an American Urological Association symptom index score >7 (n=621). Men treated for LUTS (n=168) were identified from review of medical records and/or self report. Median follow-up was 11.8 yr (interquartile range: 10.7-12.3). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Associations between self-reported LUTS, or treatment for LUTS, and risk of subsequent prostate biopsy and PCa were estimated using Cox proportional hazard models. RESULTS AND LIMITATIONS Fifty-five percent of eligible men enrolled in the study. Men treated for LUTS were more likely to undergo a prostate biopsy (hazard ratio [HR]: 2.4; 95% confidence interval [CI], 1.7-3.3). Men younger than 65 yr who were treated for LUTS were more likely to be diagnosed with PCa (HR: 2.3, 95% CI, 1.5-3.5), while men aged >65 yr were not (HR: 0.89, 95% CI, 0.35-1.9). Men with self-reported LUTS were not more likely to be biopsied or diagnosed with PCa. Neither definition of LUTS was associated with subsequent intermediate- to high-risk cancer. The study is limited by lack of histologic or prostate-specific antigen level data for the cohort. CONCLUSIONS These results indicate that a possible cause of the association between LUTS and PCa is increased diagnostic intensity among men whose LUTS come to the attention of physicians. Increased symptoms themselves were not associated with intensity of testing or diagnosis.

[1]  C. Lee,et al.  Role of androgen in prostate growth and regression: Stromal‐epithelial interaction , 1996, The Prostate. Supplement.

[2]  D. Marchant,et al.  Risk factors. , 1994, Obstetrics and gynecology clinics of North America.

[3]  M. Barry,et al.  High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. , 1998, The American journal of medicine.

[4]  I. Thompson,et al.  Epidemiology, Etiology, and Prevention of Prostate Cancer , 2012 .

[5]  D. Bostwick,et al.  The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.

[6]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[7]  R. Roberts,et al.  Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. , 2005, Mayo Clinic proceedings.

[8]  S. Freedland,et al.  Associations of benign prostatic hyperplasia with prostate cancer: the debate continues. , 2011, European urology.

[9]  J. Oesterling,et al.  Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? , 1995, Urology.

[10]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[11]  A. Wein,et al.  Campbell-Walsh Urology , 2011 .

[12]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[13]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[14]  Culley Carson,et al.  The role of dihydrotestosterone in benign prostatic hyperplasia. , 2003, Urology.

[15]  B. Högstedt,et al.  Calculated Fast-growing Benign Prostatic Hyperplasia , 2002, Scandinavian journal of urology and nephrology.

[16]  F. Schröder,et al.  Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. , 2009, European urology.

[17]  T. Wilt,et al.  Correlates and prevalence of prostatitis in a large community-based cohort of older men. , 2005, Urology.

[18]  Stig E Bojesen,et al.  Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. , 2011, European urology.

[19]  W. Sakr,et al.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.

[20]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[21]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[22]  A. Lilienfeld,et al.  Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. , 1974, Lancet.

[23]  I. Thompson,et al.  Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. , 2011, American journal of epidemiology.

[24]  D. Tindall,et al.  The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. , 2008, The Journal of urology.

[25]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.